Expanded Access Policy

Humanetics is dedicated to developing new therapies to improve the lives of patients.

Making our investigational therapy available through compassionate use or early/expanded access (an “Expanded Access Program”) is a complex matter that we have considered carefully. Providing early access to an investigational therapy can involve unknown risks, as well as an unfounded assumption of therapeutic benefit. Furthermore, an Expanded Access Program may make it harder to complete the studies necessary for the regulatory review and approval process that is ultimately the fastest path to making new therapies available to as many patients as possible.

Based on these considerations, an Expanded Access Program is not currently being offered by the company. We will continuously re-evaluate this policy.